<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20241101205100&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20241101205100&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sat, 02 Nov 2024 00:51:01 +0000</lastbuilddate>
<pubDate>Thu, 31 Oct 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Viroid-like colonists of human microbiomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39481381/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241101205100&amp;v=2.18.0.post9+e462414
      <description>Here, we describe "obelisks," a class of heritable RNA elements sharing several properties: (1) apparently circular RNA ∼1 kb genome assemblies, (2) predicted rod-like genome-wide secondary structures, and (3) open reading frames encoding a novel "Oblin" protein superfamily. A subset of obelisks includes a variant hammerhead self-cleaving ribozyme. Obelisks form their own phylogenetic group without detectable similarity to known biological agents. Surveying globally, we identified 29,959...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 23:S0092-8674(24)01091-2. doi: 10.1016/j.cell.2024.09.033. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Here, we describe "obelisks," a class of heritable RNA elements sharing several properties: (1) apparently circular RNA ∼1 kb genome assemblies, (2) predicted rod-like genome-wide secondary structures, and (3) open reading frames encoding a novel "Oblin" protein superfamily. A subset of obelisks includes a variant hammerhead self-cleaving ribozyme. Obelisks form their own phylogenetic group without detectable similarity to known biological agents. Surveying globally, we identified 29,959 distinct obelisks (clustered at 90% sequence identity) from diverse ecological niches. Obelisks are prevalent in human microbiomes, with detection in ∼7% (29/440) and ∼50% (17/32) of queried stool and oral metatranscriptomes, respectively. We establish Streptococcus sanguinis as a cellular host of a specific obelisk and find that this obelisk's maintenance is not essential for bacterial growth. Our observations identify obelisks as a class of diverse RNAs of yet-to-be-determined impact that have colonized and gone unnoticed in human and global microbiomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39481381/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241101205100&v=2.18.0.post9+e462414">39481381</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.033>10.1016/j.cell.2024.09.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39481381</guid>
<pubDate>Thu, 31 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Ivan N Zheludev</dc:creator>
<dc:creator>Robert C Edgar</dc:creator>
<dc:creator>Maria Jose Lopez-Galiano</dc:creator>
<dc:creator>Marcos de la Peña</dc:creator>
<dc:creator>Artem Babaian</dc:creator>
<dc:creator>Ami S Bhatt</dc:creator>
<dc:creator>Andrew Z Fire</dc:creator>
<dc:date>2024-10-31</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Viroid-like colonists of human microbiomes</dc:title>
<dc:identifier>pmid:39481381</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.033</dc:identifier>
</item>
<item>
<title>Ovarian cancer-derived IL-4 promotes immunotherapy resistance</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39481380/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241101205100&amp;v=2.18.0.post9+e462414
      <description>Ovarian cancer is resistant to immunotherapy, and this is influenced by the immunosuppressed tumor microenvironment (TME) dominated by macrophages. Resistance is also affected by intratumoral heterogeneity, whose development is poorly understood. To identify regulators of ovarian cancer immunity, we employed a spatial functional genomics screen (Perturb-map), focused on receptor/ligands hypothesized to be involved in tumor-macrophage communication. Perturb-map recapitulated tumor heterogeneity...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 25:S0092-8674(24)01154-1. doi: 10.1016/j.cell.2024.10.006. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Ovarian cancer is resistant to immunotherapy, and this is influenced by the immunosuppressed tumor microenvironment (TME) dominated by macrophages. Resistance is also affected by intratumoral heterogeneity, whose development is poorly understood. To identify regulators of ovarian cancer immunity, we employed a spatial functional genomics screen (Perturb-map), focused on receptor/ligands hypothesized to be involved in tumor-macrophage communication. Perturb-map recapitulated tumor heterogeneity and revealed that interleukin-4 (IL-4) promotes resistance to anti-PD-1. We find ovarian cancer cells are the key source of IL-4, which directs the formation of an immunosuppressive TME via macrophage control. IL-4 loss was not compensated by nearby IL-4-expressing clones, revealing short-range regulation of TME composition dictating tumor evolution. Our studies show heterogeneous TMEs can emerge from localized altered expression of cancer-derived cytokines/chemokines that establish immune-rich and immune-excluded neighborhoods, which drive clone selection and immunotherapy resistance. They also demonstrate the potential of targeting IL-4 signaling to enhance ovarian cancer response to immunotherapy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39481380/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241101205100&v=2.18.0.post9+e462414">39481380</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.006>10.1016/j.cell.2024.10.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39481380</guid>
<pubDate>Thu, 31 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Gurkan Mollaoglu</dc:creator>
<dc:creator>Alexander Tepper</dc:creator>
<dc:creator>Chiara Falcomatà</dc:creator>
<dc:creator>Hunter T Potak</dc:creator>
<dc:creator>Luisanna Pia</dc:creator>
<dc:creator>Angelo Amabile</dc:creator>
<dc:creator>Jaime Mateus-Tique</dc:creator>
<dc:creator>Noam Rabinovich</dc:creator>
<dc:creator>Matthew D Park</dc:creator>
<dc:creator>Nelson M LaMarche</dc:creator>
<dc:creator>Rachel Brody</dc:creator>
<dc:creator>Lindsay Browning</dc:creator>
<dc:creator>Jia-Ren Lin</dc:creator>
<dc:creator>Dmitriy Zamarin</dc:creator>
<dc:creator>Peter K Sorger</dc:creator>
<dc:creator>Sandro Santagata</dc:creator>
<dc:creator>Miriam Merad</dc:creator>
<dc:creator>Alessia Baccarini</dc:creator>
<dc:creator>Brian D Brown</dc:creator>
<dc:date>2024-10-31</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Ovarian cancer-derived IL-4 promotes immunotherapy resistance</dc:title>
<dc:identifier>pmid:39481380</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.006</dc:identifier>
</item>
<item>
<title>Multiscale organization of neuronal activity unifies scale-dependent theories of brain function</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39481379/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241101205100&amp;v=2.18.0.post9+e462414
      <description>Brain recordings collected at different resolutions support distinct signatures of neural coding, leading to scale-dependent theories of brain function. Here, we show that these disparate signatures emerge from a heavy-tailed, multiscale functional organization of neuronal activity observed across calcium-imaging recordings collected from the whole brains of zebrafish and C. elegans as well as from sensory regions in Drosophila, mice, and macaques. Network simulations demonstrate that this...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 26:S0092-8674(24)01152-8. doi: 10.1016/j.cell.2024.10.004. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Brain recordings collected at different resolutions support distinct signatures of neural coding, leading to scale-dependent theories of brain function. Here, we show that these disparate signatures emerge from a heavy-tailed, multiscale functional organization of neuronal activity observed across calcium-imaging recordings collected from the whole brains of zebrafish and C. elegans as well as from sensory regions in Drosophila, mice, and macaques. Network simulations demonstrate that this conserved hierarchical structure enhances information processing. Finally, we find that this organization is maintained despite significant cross-scale reconfiguration of cellular coordination during behavior. Our findings suggest that this nonlinear organization of neuronal activity is a universal principle conserved for its ability to adaptively link behavior to neural dynamics across multiple spatiotemporal scales while balancing functional resiliency and information processing efficiency.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39481379/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241101205100&v=2.18.0.post9+e462414">39481379</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.004>10.1016/j.cell.2024.10.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39481379</guid>
<pubDate>Thu, 31 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Brandon R Munn</dc:creator>
<dc:creator>Eli J Müller</dc:creator>
<dc:creator>Itia Favre-Bulle</dc:creator>
<dc:creator>Ethan Scott</dc:creator>
<dc:creator>Joseph T Lizier</dc:creator>
<dc:creator>Michael Breakspear</dc:creator>
<dc:creator>James M Shine</dc:creator>
<dc:date>2024-10-31</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Multiscale organization of neuronal activity unifies scale-dependent theories of brain function</dc:title>
<dc:identifier>pmid:39481379</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.004</dc:identifier>
</item>
<item>
<title>IRGQ-mediated autophagy in MHC class I quality control promotes tumor immune evasion</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39481378/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241101205100&amp;v=2.18.0.post9+e462414
      <description>The autophagy-lysosome system directs the degradation of a wide variety of cargo and is also involved in tumor progression. Here, we show that the immunity-related GTPase family Q protein (IRGQ), an uncharacterized protein to date, acts in the quality control of major histocompatibility complex class I (MHC class I) molecules. IRGQ directs misfolded MHC class I toward lysosomal degradation through its binding mode to GABARAPL2 and LC3B. In the absence of IRGQ, free MHC class I heavy chains do...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 21:S0092-8674(24)01148-6. doi: 10.1016/j.cell.2024.09.048. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The autophagy-lysosome system directs the degradation of a wide variety of cargo and is also involved in tumor progression. Here, we show that the immunity-related GTPase family Q protein (IRGQ), an uncharacterized protein to date, acts in the quality control of major histocompatibility complex class I (MHC class I) molecules. IRGQ directs misfolded MHC class I toward lysosomal degradation through its binding mode to GABARAPL2 and LC3B. In the absence of IRGQ, free MHC class I heavy chains do not only accumulate in the cell but are also transported to the cell surface, thereby promoting an immune response. Mice and human patients suffering from hepatocellular carcinoma show improved survival rates with reduced IRGQ levels due to increased reactivity of CD8+ T cells toward IRGQ knockout tumor cells. Thus, we reveal IRGQ as a regulator of MHC class I quality control, mediating tumor immune evasion.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39481378/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241101205100&v=2.18.0.post9+e462414">39481378</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.048>10.1016/j.cell.2024.09.048</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39481378</guid>
<pubDate>Thu, 31 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Lina Herhaus</dc:creator>
<dc:creator>Uxía Gestal-Mato</dc:creator>
<dc:creator>Vinay V Eapen</dc:creator>
<dc:creator>Igor Mačinković</dc:creator>
<dc:creator>Henry J Bailey</dc:creator>
<dc:creator>Cristian Prieto-Garcia</dc:creator>
<dc:creator>Mohit Misra</dc:creator>
<dc:creator>Anne-Claire Jacomin</dc:creator>
<dc:creator>Aparna Viswanathan Ammanath</dc:creator>
<dc:creator>Ivan Bagarić</dc:creator>
<dc:creator>Jolina Michaelis</dc:creator>
<dc:creator>Joshua Vollrath</dc:creator>
<dc:creator>Ramachandra M Bhaskara</dc:creator>
<dc:creator>Georg Bündgen</dc:creator>
<dc:creator>Adriana Covarrubias-Pinto</dc:creator>
<dc:creator>Koraljka Husnjak</dc:creator>
<dc:creator>Jonathan Zöller</dc:creator>
<dc:creator>Ajami Gikandi</dc:creator>
<dc:creator>Sara Ribičić</dc:creator>
<dc:creator>Tobias Bopp</dc:creator>
<dc:creator>Gerbrand J van der Heden van Noort</dc:creator>
<dc:creator>Julian D Langer</dc:creator>
<dc:creator>Andreas Weigert</dc:creator>
<dc:creator>J Wade Harper</dc:creator>
<dc:creator>Joseph D Mancias</dc:creator>
<dc:creator>Ivan Dikic</dc:creator>
<dc:date>2024-10-31</dc:date>
<dc:source>Cell</dc:source>
<dc:title>IRGQ-mediated autophagy in MHC class I quality control promotes tumor immune evasion</dc:title>
<dc:identifier>pmid:39481378</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.048</dc:identifier>
</item>
<item>
<title>Transcatheter Aortic Valve Replacement in Patients With Systolic Heart Failure and Moderate Aortic Stenosis: TAVR UNLOAD</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39480381/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241101205100&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: TAVR was not superior to AS surveillance for the primary hierarchical composite endpoint in patients with moderate AS and HFrEF on GDMT. Preemptive TAVR for moderate AS was safe and may provide clinically meaningful quality-of-life benefits.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 22:S0735-1097(24)09960-1. doi: 10.1016/j.jacc.2024.10.070. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Neurohormonal modulation and afterload reduction are key for treatment of heart failure with reduced ejection fraction (HFrEF). In HFrEF patients with concomitant moderate aortic stenosis (AS), treatment with transcatheter aortic valve replacement (TAVR) may be complementary to guideline-directed medical therapy (GDMT).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to determine whether TAVR for moderate AS provides clinical benefit in patients with HFrEF on top of GDMT.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We performed an investigator-initiated, international, randomized controlled trial in patients with HFrEF on GDMT with moderate AS who were suitable for transfemoral TAVR with a balloon-expandable valve. Patients were randomized 1:1 to TAVR or clinical aortic stenosis surveillance (CASS) with aortic valve replacement upon progression to severe AS. The primary endpoint was the hierarchical occurrence of: 1) all-cause death; 2) disabling stroke; 3) disease-related hospitalizations and heart failure equivalents; and 4) change from baseline in the Kansas City Cardiomyopathy Questionnaire Overall Summary Score analyzed using the win ratio.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: From January 2017 to December 2022, 178 patients were randomized to TAVR (n = 89) or AS surveillance (n = 89). The mean age was 77 years, 20.8% were female, and 55.6% were in NYHA functional class III or IV. The median follow-up duration was 23 months (Q1-Q3: 12-33 months). A total of 38 (43%) patients in the CASS group (of whom 35 had progressed to severe AS) underwent TAVR at a median of 12 months postrandomization. TAVR was associated with wins in 47.6% of pairs, compared with 36.6% in the CASS group, resulting in a win ratio of 1.31 (95% CI: 0.91-1.88; P = 0.14). At 1 year, TAVR resulted in a greater improvement in the Kansas City Cardiomyopathy Questionnaire Overall Summary Score compared with the CASS group (12.8 ± 21.9 points vs 3.2 ± 22.8 points; P = 0.018).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: TAVR was not superior to AS surveillance for the primary hierarchical composite endpoint in patients with moderate AS and HFrEF on GDMT. Preemptive TAVR for moderate AS was safe and may provide clinically meaningful quality-of-life benefits.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39480381/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241101205100&v=2.18.0.post9+e462414">39480381</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.070>10.1016/j.jacc.2024.10.070</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39480381</guid>
<pubDate>Thu, 31 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Nicolas M Van Mieghem</dc:creator>
<dc:creator>Sammy Elmariah</dc:creator>
<dc:creator>Ernest Spitzer</dc:creator>
<dc:creator>Philippe Pibarot</dc:creator>
<dc:creator>Tamim M Nazif</dc:creator>
<dc:creator>Jeroen J Bax</dc:creator>
<dc:creator>Rebecca T Hahn</dc:creator>
<dc:creator>Alexandra Popma</dc:creator>
<dc:creator>Ori Ben-Yehuda</dc:creator>
<dc:creator>Faouzi Kallel</dc:creator>
<dc:creator>Björn Redfors</dc:creator>
<dc:creator>Michael L Chuang</dc:creator>
<dc:creator>Maria C Alu</dc:creator>
<dc:creator>Wietze Lindeboom</dc:creator>
<dc:creator>Dhaval Kolte</dc:creator>
<dc:creator>Firas E Zahr</dc:creator>
<dc:creator>Susheel K Kodali</dc:creator>
<dc:creator>Justin A Strote</dc:creator>
<dc:creator>Renicus S Hermanides</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:creator>Jan G P Tijssen</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:date>2024-10-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Transcatheter Aortic Valve Replacement in Patients With Systolic Heart Failure and Moderate Aortic Stenosis: TAVR UNLOAD</dc:title>
<dc:identifier>pmid:39480381</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.070</dc:identifier>
</item>
<item>
<title>Quality of Life After Transcatheter Tricuspid Valve Replacement: 1-Year Results From TRISCEND II Pivotal Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39480380/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241101205100&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Compared with OMT alone, treatment of patients with symptomatic and severe or greater TR with TTVR+OMT resulted in substantial improvement in patients' symptoms, function, and quality of life. These benefits were evident 30 days after TTVR, continued to increase through 6 months, and remained durable through 1 year. (TRISCEND II Pivotal Trial [Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy using a Novel...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 22:S0735-1097(24)09954-6. doi: 10.1016/j.jacc.2024.10.067. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Severe tricuspid regurgitation (TR) often causes substantial impairment in patient-reported health status (ie, symptoms, physical and social function, and quality of life), which may improve with transcatheter tricuspid valve replacement (TTVR).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We performed an in-depth analysis of health status of patients enrolled in the TRISCEND (Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy using a Novel Device) II pivotal trial to help quantify the benefit of intervention to patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The TRISCEND II pivotal trial randomized 400 patients with symptomatic and severe or greater TR 2:1 to TTVR with the EVOQUE tricuspid valve replacement system plus optimal medical therapy (OMT) or OMT alone. Health status was assessed with the Kansas City Cardiomyopathy Questionnaire and the 36-Item Short Form Health Survey. Changes in health status over 1 year were compared between treatment groups using mixed-effects repeated-measures models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The analysis cohort included 392 patients, of whom 259 underwent attempted TTVR and 133 received OMT alone (mean age 79.2 ± 7.6 years, 75.5% women, 56.1% with massive or torrential TR). Patients had substantially impaired health status at baseline (mean Kansas City Cardiomyopathy Questionnaire Overall Summary Score [KCCQ-OS] 52.1 ± 22.8; mean 36-Item Short Form Health Survey physical component summary score 35.2 ± 8.4). TTVR+OMT patients reported significantly greater improvement in both disease-specific and generic health status at each follow-up time point. Mean between-group differences in the KCCQ-OS favored TTVR+OMT at each time point: 11.8 points (95% CI: 7.4-16.3 points) at 30 days, 20.8 points (95% CI: 16.1-25.5 points) at 6 months, and 17.8 points (95% CI: 13.0-22.5 points) at 1 year. In subgroup analyses, TTVR+OMT improved health status to a greater extent among patients with torrential or massive TR vs severe TR (treatment effect 23.3 vs 22.6 vs 11.3; interaction P = 0.049). At 1 year, 64.6% of TTVR+OMT patients were alive and well (KCCQ-OS ≥60 points and no decline of ≥10 points from baseline) compared with 31.0% with OMT alone.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Compared with OMT alone, treatment of patients with symptomatic and severe or greater TR with TTVR+OMT resulted in substantial improvement in patients' symptoms, function, and quality of life. These benefits were evident 30 days after TTVR, continued to increase through 6 months, and remained durable through 1 year. (TRISCEND II Pivotal Trial [Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy using a Novel Device]; NCT04482062).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39480380/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241101205100&v=2.18.0.post9+e462414">39480380</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.067>10.1016/j.jacc.2024.10.067</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39480380</guid>
<pubDate>Thu, 31 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Suzanne V Arnold</dc:creator>
<dc:creator>Rebecca T Hahn</dc:creator>
<dc:creator>Vinod H Thourani</dc:creator>
<dc:creator>Raj Makkar</dc:creator>
<dc:creator>Moody Makar</dc:creator>
<dc:creator>Rahul P Sharma</dc:creator>
<dc:creator>Christiane Haeffele</dc:creator>
<dc:creator>Charles J Davidson</dc:creator>
<dc:creator>Akhil Narang</dc:creator>
<dc:creator>Brian O'Neill</dc:creator>
<dc:creator>James Lee</dc:creator>
<dc:creator>Pradeep Yadav</dc:creator>
<dc:creator>Firas Zahr</dc:creator>
<dc:creator>Scott Chadderdon</dc:creator>
<dc:creator>Mackram Eleid</dc:creator>
<dc:creator>Sorin Pislaru</dc:creator>
<dc:creator>Robert Smith</dc:creator>
<dc:creator>Molly Szerlip</dc:creator>
<dc:creator>Brian Whisenant</dc:creator>
<dc:creator>Nishant Sekaran</dc:creator>
<dc:creator>Santiago Garcia</dc:creator>
<dc:creator>Terri Stewart-Dehner</dc:creator>
<dc:creator>Paul A Grayburn</dc:creator>
<dc:creator>Anna Sannino</dc:creator>
<dc:creator>Clayton Snyder</dc:creator>
<dc:creator>Yiran Zhang</dc:creator>
<dc:creator>Michael J Mack</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:creator>Philipp Lurz</dc:creator>
<dc:creator>Susheel Kodali</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:creator>TRISCEND II Pivotal Trial Investigators</dc:creator>
<dc:date>2024-10-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Quality of Life After Transcatheter Tricuspid Valve Replacement: 1-Year Results From TRISCEND II Pivotal Trial</dc:title>
<dc:identifier>pmid:39480380</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.067</dc:identifier>
</item>
<item>
<title>Randomized Comparison of Novel Low-Dose Sirolimus-Eluting Biodegradable Polymer Stent vs Second-Generation DES: TARGET-IV NA Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39480379/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241101205100&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The biodegradable polymer sirolimus-eluting stent was noninferior to currently used second-generation DES with regard to TLF at 1 year. (Firehawk® Rapamycin Target Eluting Coronary Stent North American Trial; NCT04562532).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 24:S0735-1097(24)09966-2. doi: 10.1016/j.jacc.2024.10.074. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Drug-eluting stents (DESs) with controlled antiproliferative drug release reduce restenosis risk, but durable polymers can delay healing and inhibit reendothelialization. The Firehawk biodegradable polymer sirolimus-eluting stent (BP-SES) has a fully biodegradable sirolimus-containing polymer coating localized to recessed abluminal grooves on the stent surface and delivers roughly one-third the drug dose of other DESs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We report the primary results of the TARGET-IV NA (Firehawk Rapamycin Target Eluting Coronary Stent North American Trial) randomized controlled trial comparing clinical outcomes with BP-SES vs currently used second-generation DESs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The TARGET-IV NA study was a prospective, multicenter, single-blind, 1:1 randomized noninferiority trial comparing the BP-SES with control in North America and Europe among patients undergoing percutaneous coronary intervention for chronic or acute coronary syndromes. The primary endpoint was target lesion failure (TLF) at 12 months (composite of cardiac death, target vessel-related myocardial infarction, or ischemia-driven target lesion revascularization). The primary analysis (intention-to-treat) tested noninferiority of BP-SES vs control using an absolute margin of 3.85% and 1-sided α of 0.025. Noninferiority-powered secondary endpoints were tested in an optical coherence tomography substudy (endpoint: mean neointimal hyperplasia thickness) and an angiography substudy (endpoint: in-stent late lumen loss).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 1,720 patients (mean age 66 years; 74% male) with 2,159 lesions were randomly allocated to receive either BP-SES (860 patients, 1,057 lesions) or control second-generation DES (860 patients, 1,084 lesions). A total of 61% of patients presented with stable coronary disease, 32% had unstable angina, and 7% had non-ST-segment elevation myocardial infarction (NSTEMI) or recent ST-segment elevation myocardial infarction. The rate of TLF with BP-SES was noninferior to control at 12 months (3.4% vs 3.3%, absolute risk difference 0.13%, upper bound 97.5% CI: 2.03, P<sub>noninferiority</sub> &lt; 0.0001). Cardiac death, myocardial infarction, and stent thrombosis rates were similar between groups. Angiographic follow-up was available in 104 patients (97.2% of those enrolled in the angiographic substudy) and 128 (94.1%) lesions. At 13 months, the powered secondary endpoint of mean in-stent late lumen loss was 0.149 ± 0.263 mm for BP-SES and 0.327 ± 0.463 mm for control (least squares mean difference: -0.178; 90% CI: -0.2943 to -0.0632; P<sub>noninferiority</sub> &lt; 0.0001). The optical coherence tomography substudy included 37 patients (42 lesions) with no difference in mean neointimal hyperplasia thickness between groups at 13 months (P<sub>noninferiority</sub> = 0.01).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The biodegradable polymer sirolimus-eluting stent was noninferior to currently used second-generation DES with regard to TLF at 1 year. (Firehawk® Rapamycin Target Eluting Coronary Stent North American Trial; NCT04562532).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39480379/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241101205100&v=2.18.0.post9+e462414">39480379</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.074>10.1016/j.jacc.2024.10.074</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39480379</guid>
<pubDate>Thu, 31 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Robert W Yeh</dc:creator>
<dc:creator>Olivier F Bertrand</dc:creator>
<dc:creator>Ehtisham Mahmud</dc:creator>
<dc:creator>Emanuele Barbato</dc:creator>
<dc:creator>Batla Falah</dc:creator>
<dc:creator>Melek Ozgu Issever</dc:creator>
<dc:creator>Björn Redfors</dc:creator>
<dc:creator>Alexandra Popma</dc:creator>
<dc:creator>Michael Curtis</dc:creator>
<dc:creator>Niels van Royen</dc:creator>
<dc:creator>Jean-Francois Tanguay</dc:creator>
<dc:creator>Luc Janssens</dc:creator>
<dc:creator>William N Newman</dc:creator>
<dc:creator>Koen Teeuwen</dc:creator>
<dc:creator>James W Choi</dc:creator>
<dc:creator>Maurits T Dirksen</dc:creator>
<dc:creator>Akiko Maehara</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:date>2024-10-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Randomized Comparison of Novel Low-Dose Sirolimus-Eluting Biodegradable Polymer Stent vs Second-Generation DES: TARGET-IV NA Trial</dc:title>
<dc:identifier>pmid:39480379</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.074</dc:identifier>
</item>
<item>
<title>Drug-Coated Balloon Angioplasty of the Side Branch During Provisional Stenting: The Multicenter Randomized DCB-BIF Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39480378/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241101205100&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with simple and true coronary bifurcation lesions undergoing provisional stenting, main vessel stenting with a DCB for the compromised side branch resulted in a lower 1-year rate of the composite outcome compared with an NCB intervention for the side branch. The high rates of periprocedural myocardial infarction, which occurred early and did not lead to revascularization, are of unclear clinical significance.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 21:S0735-1097(24)08451-1. doi: 10.1016/j.jacc.2024.08.067. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Side branch stenting is often required during provisional stenting, leading to suboptimal results. Drug-coated balloons (DCB) for the compromised side branch have emerged as an attractive strategy. However, the benefit of DCB for coronary bifurcations remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aimed to investigate whether DCB, compared with a noncompliant balloon (NCB), for the pinched side branch improves the outcomes of provisional stenting in patients with simple, true coronary bifurcations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this multicenter, randomized controlled trial, patients with true coronary bifurcations who had side branch diameter stenosis of ≥70% after main vessel stenting at 22 centers in China, Indonesia, Italy, and Korea were randomly assigned to either DCB or NCB intervention. The primary endpoint was major adverse cardiac events, a composite of cardiac death, target vessel myocardial infarction, or clinically driven target-lesion revascularization at the 1-year follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Between September 8, 2020, and June 2, 2023, 784 patients with true coronary bifurcation lesions undergoing main vessel stenting and having a severely compromised side branch were randomly assigned to the DCB (n = 391) or NCB (n = 393) group. One-year follow-up was completed in all patients. The primary endpoint occurred in 28 patients in the DCB group and 49 patients in the NCB group (Kaplan-Meier rate: 7.2% vs 12.5%; HR: 0.56; 95% CI: 0.35-0.88; P = 0.013), driven by a reduction in myocardial infarction. There were no significant differences between groups in procedural success, crossover to a 2-stent approach, all-cause death, revascularization, or stent thrombosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with simple and true coronary bifurcation lesions undergoing provisional stenting, main vessel stenting with a DCB for the compromised side branch resulted in a lower 1-year rate of the composite outcome compared with an NCB intervention for the side branch. The high rates of periprocedural myocardial infarction, which occurred early and did not lead to revascularization, are of unclear clinical significance.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39480378/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241101205100&v=2.18.0.post9+e462414">39480378</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.067>10.1016/j.jacc.2024.08.067</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39480378</guid>
<pubDate>Thu, 31 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Xiaofei Gao</dc:creator>
<dc:creator>Nailiang Tian</dc:creator>
<dc:creator>Jing Kan</dc:creator>
<dc:creator>Ping Li</dc:creator>
<dc:creator>Mian Wang</dc:creator>
<dc:creator>Imad Sheiban</dc:creator>
<dc:creator>Filippo Figini</dc:creator>
<dc:creator>Jianping Deng</dc:creator>
<dc:creator>Xiang Chen</dc:creator>
<dc:creator>Teguh Santoso</dc:creator>
<dc:creator>Eun-Seok Shin</dc:creator>
<dc:creator>Muhammad Munawar</dc:creator>
<dc:creator>Shangyu Wen</dc:creator>
<dc:creator>Zhengzhong Wang</dc:creator>
<dc:creator>Shaoping Nie</dc:creator>
<dc:creator>Yue Li</dc:creator>
<dc:creator>Tan Xu</dc:creator>
<dc:creator>Bin Wang</dc:creator>
<dc:creator>Fei Ye</dc:creator>
<dc:creator>Junjie Zhang</dc:creator>
<dc:creator>Xiling Shou</dc:creator>
<dc:creator>Shao-Liang Chen</dc:creator>
<dc:date>2024-10-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Drug-Coated Balloon Angioplasty of the Side Branch During Provisional Stenting: The Multicenter Randomized DCB-BIF Trial</dc:title>
<dc:identifier>pmid:39480378</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.067</dc:identifier>
</item>
<item>
<title>Drug-Coated Balloons to Keep Interventions of the Side Branch Simple (KISS): KISS or Be KISS'D</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39480377/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241101205100&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 21:S0735-1097(24)08517-6. doi: 10.1016/j.jacc.2024.09.020. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39480377/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241101205100&v=2.18.0.post9+e462414">39480377</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.020>10.1016/j.jacc.2024.09.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39480377</guid>
<pubDate>Thu, 31 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Ziad Ali</dc:creator>
<dc:creator>Celina M Yong</dc:creator>
<dc:date>2024-10-31</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Drug-Coated Balloons to Keep Interventions of the Side Branch Simple (KISS): KISS or Be KISS'D</dc:title>
<dc:identifier>pmid:39480377</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.020</dc:identifier>
</item>
<item>
<title>Cardiac Myosin Inhibition in Obstructive Hypertrophic Cardiomyopathy: Can Aficamten Stand Alone?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39477632/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241101205100&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 5;84(19):1850-1853. doi: 10.1016/j.jacc.2024.09.015.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39477632/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241101205100&v=2.18.0.post9+e462414">39477632</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.015>10.1016/j.jacc.2024.09.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39477632</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Enrico Ammirati</dc:creator>
<dc:creator>Guglielmo Gallone</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Cardiac Myosin Inhibition in Obstructive Hypertrophic Cardiomyopathy: Can Aficamten Stand Alone?</dc:title>
<dc:identifier>pmid:39477632</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.015</dc:identifier>
</item>
<item>
<title>Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39477631/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241101205100&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In FOREST-HCM, one-half of the patients with oHCM attempted downtitration and withdrawal of SoC medications while receiving aficamten treatment, with infrequent instances of resumption of SoC. Stopping and dose reduction of SoC medications were well tolerated with no adverse consequences in clinical measures of efficacy (Follow-Up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in Hypertrophic Cardiomyopathy [FOREST-HCM]; NCT04848506).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 5;84(19):1839-1849. doi: 10.1016/j.jacc.2024.09.002.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Standard-of-care (SoC) medications for the treatment of obstructive hypertrophic cardiomyopathy (oHCM) are recommended as first-line therapy despite the lack of evidence from controlled clinical trials and well known off-target side effects.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We describe the impact of SoC therapy downtitration and withdrawal in patients already receiving aficamten in FOREST-HCM (Follow-Up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in Hypertrophic Cardiomyopathy; NCT04848506).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients receiving SoC therapy (beta-blocker, nondihydropyridine calcium-channel blocker, and/or disopyramide) were eligible for protocol-guided SoC downtitration and withdrawal at the discretion of the investigator and after achieving a stable dose of aficamten for ≥4 weeks. Successful SoC withdrawal was defined as at least a 50% dose-reduction in ≥1 medication. Adverse events (AEs) were prospectively evaluated 1 to 2 weeks after any SoC withdrawal.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 145 patients with oHCM who were followed for at least 24 weeks (mean age 60.5 ± 13.2 years; 44.8% female; 42% NYHA functional class III), 136 (93.8%) were receiving ≥1 SoC therapy; of those, 64 (47%) had an attempt at withdrawal, with 59 (92.2%) successful. Thirty-eight (64.4%) patients completely discontinued ≥1 medication, and 27 (45.8%) achieved aficamten monotherapy with 2 later restarting a SoC medication. There were no significant differences in baseline characteristics on day 1 in FOREST-HCM in those with a SoC-withdrawal vs no-withdrawal attempt. In patients who underwent successful SoC therapy withdrawal, NYHA functional class improved by ≥1 class in 79.2% from baseline, Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score improved to 83.0 ± 15.8 points, and resting and Valsalva left ventricular outflow tract gradient improved to 14.3 ± 10.9 and 32.9 ± 21.4 mm Hg, respectively. N-terminal pro-B-type natriuretic peptide levels improved to a median of 220.0 pg/mL (Q1-Q3: 102.0-554.0.0 pg/mL) and high-sensitivity troponin I improved to a median of 6.0 ng/L (Q1-Q3:3.5-10.7 ng/L). Downtitration and withdrawal of SoC therapy did not impact these results (all P values for change were >;0.05), and these changes were similar in patients who did not undergo SoC therapy withdrawal. There were no serious AEs attributed to SoC withdrawal and treatment emergent AEs were similar between groups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In FOREST-HCM, one-half of the patients with oHCM attempted downtitration and withdrawal of SoC medications while receiving aficamten treatment, with infrequent instances of resumption of SoC. Stopping and dose reduction of SoC medications were well tolerated with no adverse consequences in clinical measures of efficacy (Follow-Up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in Hypertrophic Cardiomyopathy [FOREST-HCM]; NCT04848506).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39477631/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241101205100&v=2.18.0.post9+e462414">39477631</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.002>10.1016/j.jacc.2024.09.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39477631</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Ahmad Masri</dc:creator>
<dc:creator>Lubna Choudhury</dc:creator>
<dc:creator>Roberto Barriales-Villa</dc:creator>
<dc:creator>Perry Elliott</dc:creator>
<dc:creator>Martin S Maron</dc:creator>
<dc:creator>Michael E Nassif</dc:creator>
<dc:creator>Artur Oreziak</dc:creator>
<dc:creator>Anjali Tiku Owens</dc:creator>
<dc:creator>Sara Saberi</dc:creator>
<dc:creator>Albree Tower-Rader</dc:creator>
<dc:creator>Florian Rader</dc:creator>
<dc:creator>Pablo Garcia-Pavia</dc:creator>
<dc:creator>Iacopo Olivotto</dc:creator>
<dc:creator>Sherif F Nagueh</dc:creator>
<dc:creator>Andrew Wang</dc:creator>
<dc:creator>Stephen B Heitner</dc:creator>
<dc:creator>Daniel L Jacoby</dc:creator>
<dc:creator>Stuart Kupfer</dc:creator>
<dc:creator>Fady I Malik</dc:creator>
<dc:creator>Chiara Melloni</dc:creator>
<dc:creator>Lisa Meng</dc:creator>
<dc:creator>Jenny Wei</dc:creator>
<dc:creator>Mark V Sherrid</dc:creator>
<dc:creator>Theodore P Abraham</dc:creator>
<dc:creator>FOREST-HCM Investigators</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM</dc:title>
<dc:identifier>pmid:39477631</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.002</dc:identifier>
</item>
<item>
<title>TAVR in Patients with Moderate Aortic Stenosis and Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39477044/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241101205100&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 21:S0735-1097(24)10056-3. doi: 10.1016/j.jacc.2024.10.088. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39477044/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241101205100&v=2.18.0.post9+e462414">39477044</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.088>10.1016/j.jacc.2024.10.088</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39477044</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Philippe Généreux</dc:creator>
<dc:creator>Aakriti Gupta</dc:creator>
<dc:creator>Raj R Makkar</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>TAVR in Patients with Moderate Aortic Stenosis and Heart Failure</dc:title>
<dc:identifier>pmid:39477044</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.088</dc:identifier>
</item>
<item>
<title>Structure-guided discovery of bile acid derivatives for treating liver diseases without causing itch</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39476841/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241101205100&amp;v=2.18.0.post9+e462414
      <description>Chronic itch is a debilitating symptom profoundly impacting the quality of life in patients with liver diseases like cholestasis. Activation of the human G-protein coupled receptor, MRGPRX4 (hX4), by bile acids (BAs) is implicated in promoting cholestasis itch. However, the detailed underlying mechanisms remain elusive. Here, we identified 3-sulfated BAs that are elevated in cholestatic patients with itch symptoms. We solved the cryo-EM structure of hX4-Gq in a complex with 3-phosphated...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 24:S0092-8674(24)01149-8. doi: 10.1016/j.cell.2024.10.001. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Chronic itch is a debilitating symptom profoundly impacting the quality of life in patients with liver diseases like cholestasis. Activation of the human G-protein coupled receptor, MRGPRX4 (hX4), by bile acids (BAs) is implicated in promoting cholestasis itch. However, the detailed underlying mechanisms remain elusive. Here, we identified 3-sulfated BAs that are elevated in cholestatic patients with itch symptoms. We solved the cryo-EM structure of hX4-Gq in a complex with 3-phosphated deoxycholic acid (DCA-3P), a mimic of the endogenous 3-sulfated deoxycholic acid (DCA-3S). This structure revealed an unprecedented ligand-binding pocket in MRGPR family proteins, highlighting the crucial role of the 3-hydroxyl (3-OH) group on BAs in activating hX4. Guided by this structural information, we designed and developed compound 7 (C7), a BA derivative lacking the 3-OH. Notably, C7 effectively alleviates hepatic injury and fibrosis in liver disease models while significantly mitigating the itch side effects.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39476841/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241101205100&v=2.18.0.post9+e462414">39476841</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.001>10.1016/j.cell.2024.10.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39476841</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Jun Yang</dc:creator>
<dc:creator>Tianjun Zhao</dc:creator>
<dc:creator>Junping Fan</dc:creator>
<dc:creator>Huaibin Zou</dc:creator>
<dc:creator>Guangyi Lan</dc:creator>
<dc:creator>Fusheng Guo</dc:creator>
<dc:creator>Yaocheng Shi</dc:creator>
<dc:creator>Han Ke</dc:creator>
<dc:creator>Huasheng Yu</dc:creator>
<dc:creator>Zongwei Yue</dc:creator>
<dc:creator>Xin Wang</dc:creator>
<dc:creator>Yingjie Bai</dc:creator>
<dc:creator>Shuai Li</dc:creator>
<dc:creator>Yingjun Liu</dc:creator>
<dc:creator>Xiaoming Wang</dc:creator>
<dc:creator>Yu Chen</dc:creator>
<dc:creator>Yulong Li</dc:creator>
<dc:creator>Xiaoguang Lei</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Structure-guided discovery of bile acid derivatives for treating liver diseases without causing itch</dc:title>
<dc:identifier>pmid:39476841</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.001</dc:identifier>
</item>
<item>
<title>An archaic HLA class I receptor allele diversifies natural killer cell-driven immunity in First Nations peoples of Oceania</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39476840/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241101205100&amp;v=2.18.0.post9+e462414
      <description>Genetic variation in host immunity impacts the disproportionate burden of infectious diseases that can be experienced by First Nations peoples. Polymorphic human leukocyte antigen (HLA) class I and killer cell immunoglobulin-like receptors (KIRs) are key regulators of natural killer (NK) cells, which mediate early infection control. How this variation impacts their responses across populations is unclear. We show that HLA-A^(∗)24:02 became the dominant ligand for inhibitory KIR3DL1 in First...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 25:S0092-8674(24)01153-X. doi: 10.1016/j.cell.2024.10.005. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Genetic variation in host immunity impacts the disproportionate burden of infectious diseases that can be experienced by First Nations peoples. Polymorphic human leukocyte antigen (HLA) class I and killer cell immunoglobulin-like receptors (KIRs) are key regulators of natural killer (NK) cells, which mediate early infection control. How this variation impacts their responses across populations is unclear. We show that HLA-A<sup>∗</sup>24:02 became the dominant ligand for inhibitory KIR3DL1 in First Nations peoples across Oceania, through positive natural selection. We identify KIR3DL1<sup>∗</sup>114, widespread across and unique to Oceania, as an allele lineage derived from archaic humans. KIR3DL1<sup>∗</sup>114<sup>+</sup>NK cells from First Nations Australian donors are inhibited through binding HLA-A<sup>∗</sup>24:02. The KIR3DL1<sup>∗</sup>114 lineage is defined by phenylalanine at residue 166. Structural and binding studies show phenylalanine 166 forms multiple unique contacts with HLA-peptide complexes, increasing both affinity and specificity. Accordingly, assessing immunogenetic variation and the functional implications for immunity are fundamental toward understanding population-based disease associations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39476840/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241101205100&v=2.18.0.post9+e462414">39476840</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.005>10.1016/j.cell.2024.10.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39476840</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Liyen Loh</dc:creator>
<dc:creator>Philippa M Saunders</dc:creator>
<dc:creator>Camilla Faoro</dc:creator>
<dc:creator>Neus Font-Porterias</dc:creator>
<dc:creator>Neda Nemat-Gorgani</dc:creator>
<dc:creator>Genelle F Harrison</dc:creator>
<dc:creator>Suraju Sadeeq</dc:creator>
<dc:creator>Luca Hensen</dc:creator>
<dc:creator>Shu Cheng Wong</dc:creator>
<dc:creator>Jacqueline Widjaja</dc:creator>
<dc:creator>E Bridie Clemens</dc:creator>
<dc:creator>Shiying Zhu</dc:creator>
<dc:creator>Katherine M Kichula</dc:creator>
<dc:creator>Sudan Tao</dc:creator>
<dc:creator>Faming Zhu</dc:creator>
<dc:creator>Gonzalo Montero-Martin</dc:creator>
<dc:creator>Marcelo Fernandez-Vina</dc:creator>
<dc:creator>Lisbeth A Guethlein</dc:creator>
<dc:creator>Julian P Vivian</dc:creator>
<dc:creator>Jane Davies</dc:creator>
<dc:creator>Alexander J Mentzer</dc:creator>
<dc:creator>Stephen J Oppenheimer</dc:creator>
<dc:creator>William Pomat</dc:creator>
<dc:creator>Alexander G Ioannidis</dc:creator>
<dc:creator>Carmina Barberena-Jonas</dc:creator>
<dc:creator>Oceanian Genome Variation Project Consortium</dc:creator>
<dc:creator>Andrés Moreno-Estrada</dc:creator>
<dc:creator>Adrian Miller</dc:creator>
<dc:creator>Peter Parham</dc:creator>
<dc:creator>Jamie Rossjohn</dc:creator>
<dc:creator>Steven Y C Tong</dc:creator>
<dc:creator>Katherine Kedzierska</dc:creator>
<dc:creator>Andrew G Brooks</dc:creator>
<dc:creator>Paul J Norman</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>Cell</dc:source>
<dc:title>An archaic HLA class I receptor allele diversifies natural killer cell-driven immunity in First Nations peoples of Oceania</dc:title>
<dc:identifier>pmid:39476840</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.005</dc:identifier>
</item>
<item>
<title>Stem cell activity-coupled suppression of endogenous retrovirus governs adult tissue regeneration</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39476839/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241101205100&amp;v=2.18.0.post9+e462414
      <description>Mammalian retrotransposons constitute 40% of the genome. During tissue regeneration, adult stem cells coordinately repress retrotransposons and activate lineage genes, but how this coordination is controlled is poorly understood. Here, we observed that dynamic expression of histone methyltransferase SETDB1 (a retrotransposon repressor) closely mirrors stem cell activities in murine skin. SETDB1 ablation leads to the reactivation of endogenous retroviruses (ERVs, a type of retrotransposon) and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 23:S0092-8674(24)01155-3. doi: 10.1016/j.cell.2024.10.007. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Mammalian retrotransposons constitute 40% of the genome. During tissue regeneration, adult stem cells coordinately repress retrotransposons and activate lineage genes, but how this coordination is controlled is poorly understood. Here, we observed that dynamic expression of histone methyltransferase SETDB1 (a retrotransposon repressor) closely mirrors stem cell activities in murine skin. SETDB1 ablation leads to the reactivation of endogenous retroviruses (ERVs, a type of retrotransposon) and the assembly of viral-like particles, resulting in hair loss and stem cell exhaustion that is reversible by antiviral drugs. Mechanistically, at least two molecularly and spatially distinct pathways are responsible: antiviral defense mediated by hair follicle stem cells and progenitors and antiviral-independent response due to replication stress in transient amplifying cells. ERV reactivation is promoted by DNA demethylase ten-eleven translocation (TET)-mediated hydroxymethylation and recapitulated by ablating cell fate transcription factors. Together, we demonstrated ERV silencing is coupled with stem cell activity and essential for adult hair regeneration.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39476839/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241101205100&v=2.18.0.post9+e462414">39476839</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.007>10.1016/j.cell.2024.10.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39476839</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Ying Lyu</dc:creator>
<dc:creator>Soo Jin Kim</dc:creator>
<dc:creator>Ericka S Humphrey</dc:creator>
<dc:creator>Richa Nayak</dc:creator>
<dc:creator>Yinglu Guan</dc:creator>
<dc:creator>Qingnan Liang</dc:creator>
<dc:creator>Kun Hee Kim</dc:creator>
<dc:creator>Yukun Tan</dc:creator>
<dc:creator>Jinzhuang Dou</dc:creator>
<dc:creator>Huandong Sun</dc:creator>
<dc:creator>Xingzhi Song</dc:creator>
<dc:creator>Priyadharsini Nagarajan</dc:creator>
<dc:creator>Kamryn N Gerner-Mauro</dc:creator>
<dc:creator>Kevin Jin</dc:creator>
<dc:creator>Virginia Liu</dc:creator>
<dc:creator>Rehman H Hassan</dc:creator>
<dc:creator>Miranda L Johnson</dc:creator>
<dc:creator>Lisa P Deliu</dc:creator>
<dc:creator>Yun You</dc:creator>
<dc:creator>Anurag Sharma</dc:creator>
<dc:creator>H Amalia Pasolli</dc:creator>
<dc:creator>Yue Lu</dc:creator>
<dc:creator>Jianhua Zhang</dc:creator>
<dc:creator>Vakul Mohanty</dc:creator>
<dc:creator>Ken Chen</dc:creator>
<dc:creator>Youn Joo Yang</dc:creator>
<dc:creator>Taiping Chen</dc:creator>
<dc:creator>Yejing Ge</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Stem cell activity-coupled suppression of endogenous retrovirus governs adult tissue regeneration</dc:title>
<dc:identifier>pmid:39476839</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.007</dc:identifier>
</item>
<item>
<title>Validation of the Kansas City Cardiomyopathy Questionnaire in Patients With Tricuspid Regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39476153/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241101205100&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this cohort study, the KCCQ had strong psychometric properties in patients with severe TR, including reliability, responsiveness, and validity. These data support use of the KCCQ in patients with severe TR as a measure of their symptoms, function, and quality of life and also for assessing the impact of interventions, such as TTVI, in rigorously controlled trials.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 30:e244266. doi: 10.1001/jamacardio.2024.4266. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Improving patients' health status is a key goal of treating tricuspid regurgitation (TR). The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a heart failure disease-specific health status measure used to capture the health status impact of TR and the benefit of transcatheter tricuspid valve intervention (TTVI), but its validity in this clinical setting is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the psychometric properties of the KCCQ in patients with TR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: Data were pooled from patients with severe TR enrolled in 11 manufacturer-sponsored trials of TTVI. The data were transferred to the US Food and Drug Administration to harmonize and anonymize prior to analysis by an independent center. Data were collected from December 2015 to April 2023, and data analysis was performed from July to October 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Prespecified analyses included evaluation of internal consistency, reproducibility, responsiveness, construct validity, and predictive validity. Outcomes were determined using Cronbach α, score comparisons, intraclass correlation, Cohen d, Spearman correlations with best available reference measures, and association of scores and changes in scores with risk of subsequent clinical events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study cohort was composed of 2693 patients enrolled in either single-arm (n = 1517) or randomized (n = 1176) investigations of TTVI. Mean (SD) patient age was 78.6 (8.0) years, 1658 of 2693 patients (61.6%) were female, and the mean (SD) baseline KCCQ Overall Summary (KCCQ-OS) score was 50 (23). There was strong internal consistency within individual domains (Cronbach α, .77-.83). Among clinically stable patients between 1 and 6 months, there were small mean changes in KCCQ domain and summary scores (differences of -0.1 to 1.9 points), demonstrating reproducibility. In contrast, domain and summary scores of patients who underwent TTVI showed large improvements at 1 month after treatment (mean changes, 12.1-21.4 points), indicating excellent perceived responsiveness. Construct validity was moderately strong when domains were compared with best available reference measures (Spearman correlations, 0.47-0.69). In both cross-sectional and longitudinal analyses, the KCCQ-OS was associated with clinical events, with lower scores associated with an increased risk of mortality (hazard ratio, 1.34 per 10-point decrement; 95% CI, 1.22-1.47) and heart failure hospitalization (hazard ratio, 1.24 per 10-point decrement; 95% CI, 1.17-1.31).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this cohort study, the KCCQ had strong psychometric properties in patients with severe TR, including reliability, responsiveness, and validity. These data support use of the KCCQ in patients with severe TR as a measure of their symptoms, function, and quality of life and also for assessing the impact of interventions, such as TTVI, in rigorously controlled trials.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39476153/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241101205100&v=2.18.0.post9+e462414">39476153</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11525660/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241101205100&v=2.18.0.post9+e462414">PMC11525660</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4266>10.1001/jamacardio.2024.4266</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39476153</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Suzanne V Arnold</dc:creator>
<dc:creator>John A Spertus</dc:creator>
<dc:creator>Kensey Gosch</dc:creator>
<dc:creator>Shannon M Dunlay</dc:creator>
<dc:creator>Danielle M Olds</dc:creator>
<dc:creator>Philip G Jones</dc:creator>
<dc:creator>Fraser D Bocell</dc:creator>
<dc:creator>Changfu Wu</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Validation of the Kansas City Cardiomyopathy Questionnaire in Patients With Tricuspid Regurgitation</dc:title>
<dc:identifier>pmid:39476153</dc:identifier>
<dc:identifier>pmc:PMC11525660</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4266</dc:identifier>
</item>
<item>
<title>Measuring Health Status in Patients With Tricuspid Regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39476024/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241101205100&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 30. doi: 10.1001/jamacardio.2024.4287. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39476024/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241101205100&v=2.18.0.post9+e462414">39476024</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4287>10.1001/jamacardio.2024.4287</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39476024</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Eldrin F Lewis</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Measuring Health Status in Patients With Tricuspid Regurgitation</dc:title>
<dc:identifier>pmid:39476024</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4287</dc:identifier>
</item>
<item>
<title>Transcatheter Repair Versus Surgery for Atrial Versus Ventricular Functional Mitral Regurgitation - a Post-hoc Analysis of the MATTERHORN Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39475706/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241101205100&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 30. doi: 10.1161/CIRCULATIONAHA.124.072648. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39475706/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241101205100&v=2.18.0.post9+e462414">39475706</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072648>10.1161/CIRCULATIONAHA.124.072648</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39475706</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Felix Rudolph</dc:creator>
<dc:creator>Martin Geyer</dc:creator>
<dc:creator>Stephan Baldus</dc:creator>
<dc:creator>Valeria Maria De Luca</dc:creator>
<dc:creator>Torsten Doenst</dc:creator>
<dc:creator>Roman Pfister</dc:creator>
<dc:creator>Jan Gummert</dc:creator>
<dc:creator>Mirjam Kessler</dc:creator>
<dc:creator>Peter Boekstegers</dc:creator>
<dc:creator>Edith Lubos</dc:creator>
<dc:creator>Jörg Schröder</dc:creator>
<dc:creator>Holger Thiele</dc:creator>
<dc:creator>Thomas Walther</dc:creator>
<dc:creator>Malte Kelm</dc:creator>
<dc:creator>Jörg Hausleiter</dc:creator>
<dc:creator>Ingo Eitel</dc:creator>
<dc:creator>Ulrich Fischer-Rasokat</dc:creator>
<dc:creator>Alexander Bufe</dc:creator>
<dc:creator>Alexander Schmeisser</dc:creator>
<dc:creator>Hüseyin Ince</dc:creator>
<dc:creator>Philipp Lurz</dc:creator>
<dc:creator>Ralph Stephan von Bardeleben</dc:creator>
<dc:creator>Christian Hagl</dc:creator>
<dc:creator>Thilo Noack</dc:creator>
<dc:creator>Sebastian Reith</dc:creator>
<dc:creator>Harald Beucher</dc:creator>
<dc:creator>Hermann Reichenspurner</dc:creator>
<dc:creator>Wolfgang Rottbauer</dc:creator>
<dc:creator>Paul Christian Schulze</dc:creator>
<dc:creator>Wiebke Müller</dc:creator>
<dc:creator>Julia Frank</dc:creator>
<dc:creator>Claudia Michalik</dc:creator>
<dc:creator>Martin Hellmich</dc:creator>
<dc:creator>Thorsten Wahlers</dc:creator>
<dc:creator>Volker Rudolph</dc:creator>
<dc:creator>Christos Iliadis</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Transcatheter Repair Versus Surgery for Atrial Versus Ventricular Functional Mitral Regurgitation - a Post-hoc Analysis of the MATTERHORN Trial</dc:title>
<dc:identifier>pmid:39475706</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072648</dc:identifier>
</item>
<item>
<title>TAVR in Young Patients With Aortic Stenosis: Appropriate Use or Indication Creep?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39475343/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241101205100&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 30. doi: 10.1001/jamacardio.2024.4300. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39475343/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241101205100&v=2.18.0.post9+e462414">39475343</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4300>10.1001/jamacardio.2024.4300</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39475343</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Robert O Bonow</dc:creator>
<dc:creator>Patrick T O'Gara</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>TAVR in Young Patients With Aortic Stenosis: Appropriate Use or Indication Creep?</dc:title>
<dc:identifier>pmid:39475343</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4300</dc:identifier>
</item>
<item>
<title>Outcomes of Balloon-Expandable Transcatheter Aortic Valve Replacement in Younger Patients in the Low-Risk Era</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39475333/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241101205100&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Among US patients receiving BEV TAVR for severe aortic stenosis in the low-surgical risk era, those younger than 65 years represent a small subset. Patients younger than 65 years had a high burden of comorbidities and incurred higher rates of death and readmission at 1 year compared to their older counterparts. These observations suggest that heart team decision-making regarding TAVR for most patients in this age group is clinically valid.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 30:e244237. doi: 10.1001/jamacardio.2024.4237. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Guidelines advise heart team assessment for all patients with aortic stenosis, with surgical aortic valve replacement recommended for patients younger than 65 years or with a life expectancy greater than 20 years. If bioprosthetic valves are selected, repeat procedures may be needed given limited durability of tissue valves; however, younger patients with aortic stenosis may have major comorbidities that can limit life expectancy, impacting decision-making.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To characterize patients younger than 65 years who received transcatheter aortic valve replacement (TAVR) and compare their outcomes with patients aged 65 to 80 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This retrospective registry-based analysis used data on 139 695 patients from the Society for Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy (TVT) Registry, inclusive of patients 80 years and younger undergoing TAVR from August 2019 to September 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Balloon-expandable valve (BEV) TAVR with the SAPIEN family of devices.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Comorbidities (heart failure, coronary artery disease, dialysis, and others) and outcomes (death, stroke, and hospital readmission) of patients younger than 65 years compared to patients aged 65 to 80 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In the years surveyed, 13 849 registry patients (5.7%) were younger than 65 years, 125 846 (52.1%) were aged 65 to 80 years, and 101 725 (42.1%) were 80 years and older. Among those younger than 65, the mean (SD) age was 59.7 (4.8) years, and 9068 of 13 849 patients (65.5%) were male. Among those aged 65 to 80 years, the mean (SD) age was 74.1 (4.2) years, and 77 817 of 125 843 patients (61.8%) were male. Those younger than 65 years were more likely to have a bicuspid aortic valve than those aged 65 to 80 years (3472/13 755 [25.2%] vs 9552/125 001 [7.6%], respectively; P &lt; .001). They were more likely to have congestive heart failure, chronic lung disease, diabetes, immunocompromise, and end stage kidney disease receiving dialysis. Patients younger than 65 years had worse baseline quality of life (mean [SD] Kansas City Cardiomyopathy Questionnaire score, 47.7 [26.3] vs 52.9 [25.8], respectively; P &lt; .001) and mean (SD) gait speed (5-meter walk test, 6.6 [5.8] seconds vs 7.0 [4.9] seconds, respectively; P &lt; .001) than those aged 65 to 80 years. At 1 year, patients younger than 65 years had significantly higher readmission rates (2740 [28.2%] vs 23 178 [26.1%]; P &lt; .001) and all-cause mortality (908 [9.9%] vs 6877 [8.2%]; P &lt; .001) than older patients. When propensity matched, younger patients still had higher 1-year readmission rates (2732 [28.2%] vs 2589 [26.8%]; P &lt; .03) with similar mortality to their older counterparts (905 [9.9%] vs 827 [10.1%]; P = .55).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Among US patients receiving BEV TAVR for severe aortic stenosis in the low-surgical risk era, those younger than 65 years represent a small subset. Patients younger than 65 years had a high burden of comorbidities and incurred higher rates of death and readmission at 1 year compared to their older counterparts. These observations suggest that heart team decision-making regarding TAVR for most patients in this age group is clinically valid.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39475333/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241101205100&v=2.18.0.post9+e462414">39475333</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11525662/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241101205100&v=2.18.0.post9+e462414">PMC11525662</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4237>10.1001/jamacardio.2024.4237</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39475333</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Megan Coylewright</dc:creator>
<dc:creator>Kendra J Grubb</dc:creator>
<dc:creator>Suzanne V Arnold</dc:creator>
<dc:creator>Wayne Batchelor</dc:creator>
<dc:creator>Abhijeet Dhoble</dc:creator>
<dc:creator>Aaron Horne</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:creator>Vinod Thourani</dc:creator>
<dc:creator>Tamim M Nazif</dc:creator>
<dc:creator>Brian R Lindman</dc:creator>
<dc:creator>Molly Szerlip</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Outcomes of Balloon-Expandable Transcatheter Aortic Valve Replacement in Younger Patients in the Low-Risk Era</dc:title>
<dc:identifier>pmid:39475333</dc:identifier>
<dc:identifier>pmc:PMC11525662</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4237</dc:identifier>
</item>
<item>
<title>Comparison of strategies for vascular ACCESS closure after transcatheter aortic valve implantation: the ACCESS-TAVI randomized trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39474906/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241101205100&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: With regard to the composite of major or minor access-related vascular complications, a combined suture-/plug-based VCD strategy was superior to a suturebased VCD strategy for vascular access closure in patients undergoing TF-TAVI.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 29:ehae784. doi: 10.1093/eurheartj/ehae784. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Data from randomized trials investigating different access closure strategies after transfemoral transcatheter aortic valve implantation (TF-TAVI) remain scarce. In this study, two vascular closure device (VCD) strategies to achieve hemostasis after TF-TAVI were compared.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The ACCESS-TAVI (Comparison of Strategies for Vascular ACCESS Closure after Transcatheter Aortic Valve Implantation) is a prospective, multicenter trial in which patients undergoing TF-TAVI were randomly assigned to a strategy with a combined suture-/plug-based VCD strategy (suture/plug group) using one ProGlideTM/ProStyleTM (Abbott Vascular) and one Angio-Seal® (Terumo) versus a suture-based VCD strategy (suture-only group) using two ProGlidesTM/ProStylesTM. The primary endpoint was a composite of major or minor access site-related vascular complications during index hospitalization according to Valve Academic Research Consortium (VARC)-3 criteria. Key secondary endpoints included time to hemostasis, VARC-3 bleeding type ≥2 and all-cause mortality over 30 days.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Between September 2022 and April 2024, 454 patients were randomized. The primary endpoint occurred in 27% (62/230) in the suture/plug group and 54% (121/224) in the suture-only group (relative risk [RR] 0.55 [95% confidence interval: 0.44;0.68]; p&lt;0.001). Time to hemostasis was significantly shorter in the suture/plug group compared to the suture-only group (108±208 s vs. 206±171 s; p &lt;0.001). At 30 days, bleeding type ≥2 occurred less often in the suture/plug group compared to the sutureonly group (6.2% vs. 12.1%, RR 0.66 [0.43;1.02]; p=0.032), with no significant difference in mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: With regard to the composite of major or minor access-related vascular complications, a combined suture-/plug-based VCD strategy was superior to a suturebased VCD strategy for vascular access closure in patients undergoing TF-TAVI.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39474906/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241101205100&v=2.18.0.post9+e462414">39474906</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae784>10.1093/eurheartj/ehae784</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39474906</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Tobias Rheude</dc:creator>
<dc:creator>Hendrik Ruge</dc:creator>
<dc:creator>Niklas Altaner</dc:creator>
<dc:creator>Costanza Pellegrini</dc:creator>
<dc:creator>Hector Alvarez Covarrubias</dc:creator>
<dc:creator>N Patrick Mayr</dc:creator>
<dc:creator>Salvatore Cassese</dc:creator>
<dc:creator>Sebastian Kufner</dc:creator>
<dc:creator>Yousuke Taniguchi</dc:creator>
<dc:creator>Christian Thilo</dc:creator>
<dc:creator>Markus Klos</dc:creator>
<dc:creator>Magdalena Erlebach</dc:creator>
<dc:creator>Simon Schneider</dc:creator>
<dc:creator>Martin Jurisic</dc:creator>
<dc:creator>Karl-Ludwig Laugwitz</dc:creator>
<dc:creator>Rüdiger Lange</dc:creator>
<dc:creator>Heribert Schunkert</dc:creator>
<dc:creator>Adnan Kastrati</dc:creator>
<dc:creator>Markus Krane</dc:creator>
<dc:creator>Erion Xhepa</dc:creator>
<dc:creator>Michael Joner</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Comparison of strategies for vascular ACCESS closure after transcatheter aortic valve implantation: the ACCESS-TAVI randomized trial</dc:title>
<dc:identifier>pmid:39474906</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae784</dc:identifier>
</item>





























</channel>
</rss>